February 07, 2013 at 07:01 AM EST
CollabRx Releases Second Generation Lung Cancer Clinical Decision Support Tool for Oncologists

SAN FRANCISCO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX) today announced the release of a new version of its Therapy Finder™application ("app") for lung cancer. The lung cancer Therapy Finder™app is a web-based decision support tool that enables oncologists to take into account the genetics of a patient's tumor when determining a treatment plan. The newest lung cancer Therapy Finder™ is currently freely available at the company's website and via distribution partners such as MedPage Today, Everyday Health's physician portal (http://www.medpagetoday.com/resource-center/lung-cancer-therapy/therapy-finder).

This "second generation" version of the Therapy Finder™ incorporates into its proprietary rules-based algorithm and decision tables the results of recent advances in lung cancer clinical and translational research by addressing the ROS1 biomarker as a potentially relevant molecular subtype and diagnostic test for lung cancer. Patients who are ROS1-positive may be candidates for the Pfizer c-MET/ALK inhibitor Xalkori (crizotinib) and other ALK inhibitors available in clinical trials. Other significant updates include additional information and clinical context of the AstraZeneca investigational drug selumetinib.

The app content is kept dynamically up-to-date by internal CollabRx scientists using the company's proprietary semantic integration platform, a technology developed by CollabRx to enable the efficient and semi-automated gathering, annotation, and curation of the world's knowledge on molecular medicine for oncology. In support of these activities, CollabRx is advised by an independent board of independent lung cancer experts, led by Ravi Salgia, MD, PhD, a professor of Medicine at the University of Chicago. Other lung cancer expert advisory board members are affiliated with hospitals and cancer treatment centers at the University of Colorado, Harvard Medical School, University of Pittsburgh, Johns Hopkins Medical School, The Ohio State University, and the Medical University of South Carolina. Many of these advisors use the lung cancer Therapy Finder™ app in promoting patient/physician engagement when treating lung cancer patients at their own institutions.

"Therapy Finder™ apps are the first of a larger set of related products being developed by CollabRx to support physician clinical decision making," said Thomas Mika, President & CEO of CollabRx. "We are developing additional tools for all common cancer types and extending their reach to address issues important to pathologists and diagnostic laboratories, as well as physicians treating patients with earlier stage disease and the prevention and early detection of cancer, in support of our overall strategy to be the primary source for clinically-relevant, actionable information for use by physicians at the point of care."

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

The CollabRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16990

CONTACT: Thomas R. Mika, CEO
         CollabRx, Inc.
         415-248-5350
         
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         robert.ferri@robertferri.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here